Evidence map›Paper›PMID 11742499›Full record

ArticleBritish journal of cancer2001

Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism.

E Asham, A Shankar, M Loizidou, S Fredericks, K Miller, P B Boulos, G Burnstock, I Taylor

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 116 citations in OpenAlex.

  1. Trial
  2. Metabolic underpinnings of cancer-related fatigue.American journal of physiology. Endocrinology and metabolism · 2024
    Review
  3. Repurposing of the Drug Tezosentan for Cancer Therapy.Current issues in molecular biology · 2023
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Bioinformatic analyses revealed underlying biological functions correlated with oxaliplatin responsiveness.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Circulating levels of endothelin-1 (ET-1) and its precursor (Big ET-1) in breast cancer early diagnosis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. [Expression and clinical relevance of uPA and ET-1 in non-small cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

E AshamDepartments of Surgery, Histopathology, The Royal Free and University College Medical School, 67-73 Riding House Street, London, UK.
A Shankar
M Loizidou
S Fredericks
K Miller
P B Boulos
G Burnstock
I Taylor
St George's, University of London · GBThe Royal Free Hospital · GBUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelin-1 (ET-1) is a vasoconstrictor peptide which stimulates proliferation in vitro in different cell types, including colorectal cancer cells. Raised ET-1 levels have been detected both on tissue specimens and in the plasma of patients with cancers. To investigate the role of ET-1 in colorectal cancer: (i) ET-1 plasma levels in patients with colorectal cancer were measured by radioimmunoassay: group 1 = controls (n = 22), group 2 = primary colorectal cancer only (n = 39), group 3 = liver metastases only (n = 26); (ii) ET-1 expression in primary colorectal cancer specimens (n =10) was determined immunohistochemically and (iii) the effect of intraportally infused antagonists to the two ET-1 receptors, ET(A) and ET(B), on the growth of liver metastases in a rat model was assessed. ET-1 plasma levels were significantly increased in both patients with primary tumour and patients with metastases, compared to controls (P < 0.01, 3.9 +/- 1.4, 4.5 +/- 1.5, vs. 2.75 +/- 1.37 pg/ml, respectively). Immunohistochemically, strong expression of ET-1 was found in the cytoplasm, stroma and blood vessels of cancers, unlike the normal colon where only the apical layer of the epithelium, vascular endothelial cells and surrounding stroma were positively stained. In the rat model, there was significant reduction in liver tumour weights compared to controls, following treatment with the ET(A) antagonist (BQ123) 30 min after the intraportal inoculation of tumour cells (P < 0.05). These results suggest ET-1 is produced by colorectal cancers and may play a role in the growth of colorectal cancer acting through ET(A) receptors. ET(A) antagonists are indicated as potential anti-cancer agents.

Indexed as

Endothelin Receptor AntagonistsAdultAgedAged, 80 and overAnimalsColonColorectal NeoplasmsEndothelin-1FemaleHumansImmunohistochemistryLiver NeoplasmsMaleMiddle AgedNeoplasms, ExperimentalNeoplasm TransplantationA 192621cyclo(Trp-Asp-Pro-Val-Leu)Endothelin-1Endothelin Receptor AntagonistsOligopeptidesPD 142893Peptides, CyclicPyrrolidinesReceptor, Endothelin AReceptor, Endothelin B

Identifiers

PMID11742499
PMCPMC2363991
OpenAlexW1590661230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.